Scientists have discovered the first drug of its kind that appears to slow the pace of mental decline in Alzheimer’s patients.
Solanezumab, developed by the American pharmaceutical company Eli Lilly, was shown to block memory loss in patients with a mild version of the disease, making it the first medicine ever to slow pace of damage to patients’ brains.
Existing drugs, such as Aricept, can manage only the symptoms of dementia by helping the dying brain cells function, but Solanezumab attacks the deformed proteins that build up in the brain during Alzheimer’s.
Dr Doug Brown, head of research at the Alzheimer’s Society, said: “Today’s findings strongly suggest that targeting people in the earliest stages of Alzheimer’s disease with these antibody treatments is the best way to slow or stop Alzheimer’s disease. These drugs are able to reduce the sticky plaques of amyloid that build up in the brain, and now we have seen the first hints that doing this early enough may slow disease progression.”
Should further trial results be positive, it could still be up to several years before the drug would become available on the NHS. Another phase-three trial is due to report in 2016 and then the drug would need to go through regulatory approval and would need to be shown to be sufficiently beneficial to patients.
Image credit: Ann Gordon
At Kinetica, we are always on the hunt for new talent to join our team and have recently had the pleasure of recruiting our newest member – Liz Holdsworth.
Liz has five years’ experience in the recruitment industry – four of which have been spent in the pharmaceutical and medical device markets.
Since joining Kinetica, Liz has focussed her efforts purely in the pharmaceutical sector, as this is where her strongest professional relationships have been built with clients and candidates alike.
With a genuine interest in the pharmaceutical industry, Liz can often be found pouring over articles and news items on the movements and progress of technology and science in this area.
Liz specialises in mid to senior level appointments, covering functions such as: Quality & Regulatory, Technical, R&D, Engineering & Manufacturing, Sales & Marketing, Operations Management and Continuous Improvement. She recruits both permanent and contract roles, and geographically covers the UK and Europe (Liz is also SECO registered for Swiss recruitment.)
Liz is a proven headhunter and a large majority of her work is exclusive or retained due to her impressive success rates. She has never placed a candidate in a role that didn’t prove fruitful, and can boast of 100% rebate-free track record.
If you are seeking an opportunity in the pharmaceutical sector, give Liz a call on 0113 261 71 81 or email email@example.com or connect with her on LinkedIn here.
Scientists have created the first new antibiotic in 30 years – and say it could be the key to beating superbug resistance.
The new antibiotic is extracted from soil bacteria and can kill a huge range of disease-causing microbes, with scientists claiming it appears to be as good, or even better, than many existing drugs with the potential to work against a broad range of fatal infections such as pneumonia and tuberculosis.
Laboratory tests have shown the new antibiotic, teixobactin, can kill some bacteria as quickly as established antibiotics and can cure laboratory mice suffering from bacterial infections with no toxic side-effects.
Studies have also revealed the prototype drug works against harmful bacteria in a unique way that is highly unlikely to lead to drug-resistance – one of the biggest stumbling blocks in developing new antibiotics.
With fears that the world is running out of effective antibiotics given the rapid rise of drug-resistant strains of superbugs, this development could represent a huge boost for medicine. Clinical trials could begin in two years.
Image credit: marlo